{
    "Trade/Device Name(s)": [
        "Direct HDL Cholesterol (HDL)"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K153435",
    "Predicate Device Reference 510(k) Number(s)": [
        "K982341"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "LBS"
    ],
    "Summary Letter Date": "November 24, 2015",
    "Summary Letter Received Date": "November 27, 2015",
    "Submission Date": "January 6, 2016",
    "Regulation Number(s)": [
        "21CFR862.1475"
    ],
    "Regulation Name(s)": [
        "Lipoprotein test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "HDL Cholesterol"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Lithium Heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "RX Daytona plus analyzer",
        "RX Imola system"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic Endpoint Method",
        "Rate method",
        "Single point calibration"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Direct HDL Cholesterol assay using enzymatic endpoint method for quantitative measurement of HDL cholesterol in serum and plasma",
    "Indications for Use Summary": "For the quantitative in vitro determination of HDL Cholesterol in serum and plasma, used in diagnosis and treatment of lipid disorders, atherosclerosis, liver and renal diseases, and for cardiovascular disease risk assessment",
    "fda_folder": "Clinical Chemistry"
}